An Update on Further Progression of NAFLD, NASH with Prospective Therapies Like L-Carnitine (LC), Nicotinamide Ribose (NR) Combination, as well as Apical Sodium Dependent Bile Acids Transporter (ASBT) or Volixibat and Silybin as Alternatives

Inflammatory Myofibroblastic Tumor Refractory to Three Lines of ALK Inhibitors and Combination Immunotherapy

Cardiovascular Emergency, Future Direction

Asymptomatic COVID-19 Infection in Pregnancy: Underlying Threat in Refugees’ Camps in Greece